Abstract
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK
Highlights
S/GSK1349572(572) showed potent activity in Phase 2 studies in INI-naive HIV-infected subjects and limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro
of this pilot study was observed with a strong correlation between baseline susceptibility
GSK1349572 was generally well tolerated in this advanced population
Summary
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961). J Eron, JM Livrozet, P Morlat, A Lazzarin, C Katlama, T Hawkins, T Fujiwara, R Cuffe, C Vavro, J Santiago, M Ait-Khaled, S Min9*, JM Yeo. From Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK. From Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 7-11 November 2010
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
